Sales & Marketing

Patient centricity and access highlight keys to success for new development.

Harvard Business School Professor Joseph B. Fuller talks about the future prospects for pharma sales forces as they face more restrictions on accessing their target physicians and looming concerns of automation.

Pandemic-reinforced principles of successful drug launch.

In today’s fragmented commercial environment, navigating a more complex set of challenges while adapting new approaches to product launch is critical for biopharma brand teams.

Coordination of KOL engagement is all but impossible if the information an organization collects about them is fragmented. What is needed is a centralized database that captures all information about an expert from the multiple touch points across functions and geographies.

Now regulatory review teams have found a way to accelerate their processes — processes not particularly suited to speed — without compromising quality, accuracy, or adherence to regulations, how can this pace be maintained as we emerge from the pandemic?

Storytelling can be used very effectively to communicate with medical professionals without compromising the science, writes Stacey Rivkin.

COVID-19 has been game-changing for pharma sales, driving demand for new models and reps with the right competencies and skills to succeed in a hybrid sales environment.

Evolving preferences of HCPs during the pandemic have put an emphasis on learning new skillsets for pharma reps.

at some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?

Audio platforms provide new opportunities for pharma.

On examination of the challenge and strategies, lack of adherence is in and of itself a preventable disease.

Merging strengths of traditional behavioral and attitudinal research, capability enables pharmaceutical field teams to prioritize resources, targets, and outreach strategies.

Examining the key biopharma stock numbers and industry trends from a year that challenged the conduct of business and market stability like never before.

FDA issues a sharp warning letter rebuking AcelRx Pharmaceuticals for its ”glib and simplistic” messaging on painkiller Dsuvia.

Melissa Fellner of AstraZeneca and Leonie Goddard of Veeva, talk to Pharm Exec about how AZ’s mission to transform its digital strategies to better connect with customers.

Adoption of digital by biopharma reps has added an element of flexibility to their engagement strategies, resulting in better communications with HCPs.

If telehealth is here to stay, how is the industry adjusting?

What the industry has learned navigating the pandemic and what the future holds for field teams.

Todd Nichols, chief commercial officer of Alkermes, gives his top three recommendations for going all-in to digitally transform the frontline sales team.

Understanding the changes in day-to-day life for physicians during COVID and how life science executives can address them.

Companies recognize that their success with digital starts with accurate customer data, but many struggle to manage the overwhelming volume of different data types from hundreds of sources.

Following the introduction this week MyVeeva for Doctors, Veeva’s Paul Shawah discusses the background to the product and the role biopharma companies will play in its ongoing development.

A deep-dive into how pharma companies can apply service operations principles to achieve a greater level of marketing and promotional review committee satisfaction.

Pharma marketers can use their "voice" to increase prominence in advertising.